Data Presented at SABCS Demonstrate Significant Promise of Precede Biosciences’ Novel Liquid Biopsy Platform Define HER2 and ER Status in Patients With Advanced Breast Cancer

2023 SABCS Poster: Liquid biopsy determination of HER2 status in breast cancer: results from a novel epigenomic platform

Data Demonstrating Precede Biosciences' Ability Determine HER2 Status from 1mL of Plasma to be Presented at 2023 San Antonio Breast Cancer Symposium

Presents Poster on Precision Immuno-Oncology at 7th International Cancer Immunotherapy Conference in Milan, Italy

Precede Biosciences Unveils Groundbreaking Clinical Data for its Pioneering Liquid Biopsy Platform at ESMO 2023 and Simultaneously Publishes in Nature Medicine

Liquid biopsy epigenomic profiling for cancer subtyping

Madrid 2023 Esmo: Clinical subtyping of cancer from plasma based on comprehensive epigenomic profiling

Precede Biosciences First Scientific Data from its Liquid Biopsy Platform to be Presented as an Oral Presentation at ESMO 2023

Precede Biosciences Emerges from Stealth to Dramatically Impact Precision Medicine with a First-in-Class Liquid Biopsy Platform

First Patient Dosed in Phase 1a/b Clinical Trial of NPX267, a Novel Therapeutic Targeting KIR3DL3 Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors

Biotech 2050 Podcast Episode 160: Bio Special: New Vision for Immunotherapy, Detlev Biniszkiewicz, Founder and CEO, NextPoint Tx

Axel Hoos, MD, PhD, Joins Board of Directors

Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer

$80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures Advance Novel Immuno-Oncology Programs

NextPoint Therapeutics Presents Poster on NPX267 at 37th SITC Annual Meeting in Boston, MA

Sanofi backs $100M round for startup targeting immune system diseases